Clinical TrialJun 15, 2026, 07:01 AM
Axsome Therapeutics Presents New Data on AXS-12 & Solriamfetol at SLEEP 2026
AI Summary
Axsome Therapeutics announced presentations of new data on its drug candidates AXS-12 and solriamfetol at the SLEEP 2026 annual meeting. The presentations include cognitive and functional outcomes from the Phase 3 ENCORE trial of AXS-12 in narcolepsy with cataplexy, and a post-hoc analysis of Phase 3 trials for solriamfetol in excessive daytime sleepiness. Additionally, a subgroup analysis from the CRESCENDO survey on symptom burden and quality of life in narcolepsy patients with residual cataplexy will be presented.
Key Highlights
- Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026.
- AXS-12 data included cognitive and functional outcomes from the Phase 3 ENCORE trial.
- Solriamfetol data was a post-hoc analysis of Phase 3 trials for excessive daytime sleepiness.
- A subgroup analysis from the CRESCENDO survey on narcolepsy patients was also presented.
Price Impact
More from AXSM